文献速递痛风与晶体性关节病

痛风系统性炎症及达标降尿酸治疗的影响

Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy.
PubMed 文献 · Rheumatology (Oxford) · 2025-12-14

结果显示痛风患者基线存在独特的循环炎症标志物模式,炎症评分较对照升高,且经达标降尿酸治疗后在24周和48周较基线下降。

要点

  • 痛风患者基线炎症评分显著高于非痛风对照(p<0.001)。
  • 达标降尿酸治疗24周和48周后炎症评分较基线下降(p=0.01和p<0.001)。
  • 高血压和较高基线血尿酸与炎症评分升高相关。

核心结论

  • 痛风以独特的循环炎症生物标志物模式为特征,达标降尿酸治疗可使这些标志物随时间变化并趋近对照水平。

研究设计与样本

  • 病例对照与纵向队列研究,利用STOP Gout研究部分参与者的纵向血清样本及单中心生物样本库非痛风对照的单次样本。
  • 生成代表与痛风相关主成分的标准化炎症评分,比较对照与痛风患者及痛风患者随时间的变化。
  • 采用广义估计方程评估临床因素与炎症评分随时间变化的交互作用。

主要发现

  • 校正协变量后,痛风患者基线(n=278)与对照(n=275)在5个主成分上存在统计学差异。
  • 痛风患者在三个时间点的平均炎症评分均高于对照(p<0.001)。
  • 痛风患者24周(p=0.01)和48周(p<0.001)炎症评分较基线下降。
  • 较高基线评分和时间与炎症评分降低相关,而高血压和较高基线血清尿酸与炎症评分升高相关。

临床怎么用

  • 达标降尿酸治疗不仅用于预防痛风发作,也可能有助于减轻系统性炎症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We tested the hypotheses that individuals with gout would have distinct circulating inflammatory biomarker patterns compared with non-gout controls and that these differences would be attenuated with highly-effective urate-lowering therapy (ULT). METHODS: This case-control and longitudinal cohort study utilized longitudinal serum samples from a subset of participants from the STOP Gout study and non-gout controls from an institutional biobank at a single time point. Twenty pre-selected inflammatory and cardiometabolic biomarkers were measured and varimax-rotated principal component analysis (PCA) performed. An inflammatory score was generated using standardized biomarker values representing PCs associated with gout and compared between controls and gout patients, and among gout patients over time. A generalized estimating equation was used to assess interactions between clinical factors and change in inflammatory score over time. RESULTS: Five PCs statistically differed in gout (n = 278) at baseline vs. controls (n = 275) after accounting for covariates. Mean inflammatory scores of gout cases at all three time points were increased vs. controls (p < 0.001). There was a decrease in inflammatory scores at both 24- (p = 0.01) and 48-weeks (p < 0.001) vs. baseline among gout cases. Higher baseline score and time were associated with reductions in inflammatory score, whereas hypertension and higher baseline serum urate were associated with an increased inflammatory score. CONCLUSION: Gout is characterized by distinct patterns of circulating inflammatory biomarkers and these appear to change over time with treat-to-target ULT to approximate controls. This study supports the importance of treat-to-target ULT in gout management not only for flare prevention, but also to mitigate systemic inflammation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Wheeler AM, Ourada TJ, Jones SQ, et al. Systemic inflammation in gout and the impact of treat-to-target urate-lowering therapy. Rheumatology (Oxford). 2025. PMID: 41390970. doi:10.1093/rheumatology/keaf680

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。